You are on page 1of 1

Table of Contents

The number of shares of common stock deemed outstanding and used in the denominator for determining percentage ownership for each person equals (i) 10,657,564 shares of common stock outstanding as of December 31, 2010, plus (ii) such number of shares of common stock as are issuable pursuant to options, warrants or convertible securities held by that person (and excluding options, warrants and convertible securities held by other persons) which may be exercised within 60 days of December 31, 2010. The following table assumes shares are sold in this offering. We have granted the underwriter the right to purchase up to shares of our common stock and the selling stockholder has granted the underwriter the right to purchase up to 100,000 additional shares of our common stock, in each case within 30 days after the date of this prospectus, to cover any over-allotments. The following table assumes that the underwriter exercises its over-allotment option in full.
Shares Beneficially Owned Prior to Offering Number
(2)

Percent

Shares Being Offered in Over-Allotment Option

Shares Beneficially Owned After this Offering Number Percent

Beneficial Owners more than 5% (1)(2) Phronesis Partners, L.P. 180 E. Broad Street #1704 Columbus, OH 43215 (3) Quest Diagnostics Incorporated 1290 Wall Street West Lyndhurst, NJ 07071 (4) S.A.C. Capital Associates 72 Cummings Point Road Stamford, CT 06902 (5) Columbia Wanger 227 W. Monroe St. Suite 3000 Chicago, IL 60606 (6)(7) Pike Capital Management LLC 340 Madison Avenue, 19th Floor New York, NY 10173 Directors and Named Executive Officers: (8) James S. Burns (9) John F. Hamilton (10) Eric T. Fung, M.D., Ph.D. (11) Gail S. Page Peter S. Roddy William C. Wallen, Ph.D. Carl Severinghaus Sandra A. Gardiner William Creech Ashish Kohli All Directors and Executive Officers as a Group (10 persons) * (1) (2) (3)

771,090 1,271,071 964,351 919,254 620,014

7.24% 11.48% 9.05% 8.63% 5.82%

771,090 1,271,071 964,351 919,254 620,014

% % % % %

103,822 93,422 108,116 337,375 15,500 22,000 11,500 1,600 4,500 697,835

* * 1.00% 3.10% * * * * * * 6.30%

100,000 100,000

103,822 93,422 108,116 237,375 15,500 22,000 11,500 1,600 4,500 597,835

* * * % * * * * * * %

Less than 1%. Based on information set forth in the Schedule 13G/A filed by Phronesis Partners, L.P. with the SEC on February 17, 2010. James E. Wiggins is the general partner of Phronesis Partners, L.P. and exercises sole voting and investment control over the shares owned by Phronesis Partners, L.P Includes 410,476 shares issuable pursuant to warrants exercisable within 60 days of December 31, 2010. Quest Diagnostics Incorporated is a publiclyheld company. Quest Diagnostics Incorporated's executive officers are responsible for running the business of the company and thus, exercise voting and investment control over the shares and warrants owned by Quest Diagnostics Incorporated. 83